Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Current Liabilities (2023 - 2025)

CG Oncology filings provide 3 years of Total Current Liabilities readings, the most recent being $30.8 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 44.31% to $30.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.8 million, a 44.31% increase, with the full-year FY2025 number at $30.8 million, up 44.31% from a year prior.
  • Total Current Liabilities hit $30.8 million in Q4 2025 for CG Oncology, up from $30.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $30.8 million in Q4 2025 to a low of $10.0 million in Q1 2024.
  • Median Total Current Liabilities over the past 3 years was $21.4 million (2024), compared with a mean of $20.8 million.
  • The widest YoY moves for Total Current Liabilities: up 156.31% in 2025, down 44.31% in 2025.
  • CG Oncology's Total Current Liabilities stood at $14.3 million in 2023, then surged by 49.91% to $21.4 million in 2024, then skyrocketed by 44.31% to $30.8 million in 2025.
  • The last three reported values for Total Current Liabilities were $30.8 million (Q4 2025), $30.5 million (Q3 2025), and $30.4 million (Q2 2025) per Business Quant data.